Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 426

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 426
---
oun Bang has been the Chief Financial Officer of the Company
since February 14, 2025. Mr. Bang has also been the Chief Financial Officer of OSR, a position he has held since June 2024. Mr. Bang
is responsible for planning, managing and running overall finance activities of OSR and its subsidiary companies, including producing
the group’s consolidated financial statements for external audits. Previously, Mr. Bang served as chief operating officer for
Newlake Alliance Management Co., Ltd., a private equity firm based in Seoul, South Korea, from February 2019 to June 2024, where
he led private equity investments, managed fund raising and managed the organization. Mr. Bang previously served as team head, equity
capital markets, and other positions for Shinhan Securities Co. Ltd., in South Korea. Mr. Bang is a certified public accountant
in the U.S., a certified credit analyst in Korea and a certified investment manager in Korea. Mr. Bang received his B.A. in Business
Administration from Hansung University in 2002.

Dr. Constance Höfer has been the Chief Scientific Officer
of the Company since March 24, 2025. Dr. Höfer is a seasoned leader in drug development with over 20 years of experience in oncology
and immunology and will oversee OSR Holdings’ scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from
Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held
senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs
across various modalities, including New Biological Entities (NBEs), New Chemical Entities (NCEs), nucleotides, and viral and cell-based
therapies. Coupled with her extensive industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has
a strong foundation in clinical pharmacology and translational medicine, ensuring a seamless transition from early-stage research to successful
clinical development.

Phil Geon Lee has been a Director of the Company since May 2024.
Mr. Lee possesses over 20 years of experience in legal and investment fields. His areas of expertise cover a range of fund classes,
including regulatory, transactional, and hedge funds, and encompass knowledge of financial regulatory frameworks in various jurisdictions